INDICATION

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

ABECMA® Information and Resources for Nurses

As a nurse, you play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get the information and tools you need to help support your patients below.

From clinical trial data to monitoring and management information, it’s all here—so you can continue to help your patients feel comfortable and secure throughout their treatment journey.

RRMM=relapsed/refractory multiple myeloma.

Find Support and Resources for You and Your Patients with RRMM

Resources for you:

Clinician Guide for Nurses

DOWNLOAD

Nurse-to-Patient Dialogue Tool

DOWNLOAD

AE Management Tool

DOWNLOAD

Resources for your patients:

Patient Brochure

DOWNLOAD

Questions to Ask Your Doctor

DOWNLOAD

Patient Eligibility Guide

DOWNLOAD

Access and financial resources

Cell Therapy 360®

Dedicated to providing solutions-oriented support and knowledge to help patients throughout the CAR T cell therapy journey.

Bristol Myers Squibb’s Cell Therapy 360 program supports patients and caregivers throughout their treatment journey, from enrollment through the initial post-infusion monitoring period, with referral resources, patient support navigators, logistical support, financial support, and wearable technology for post-infusion monitoring.

*Eligibility requirements may apply.

Post-infusion monitoring support

Patients can receive a disposable wearable technology during the initial post-infusion monitoring period to help track their temperature in real time through their smartphone when outside the treatment center.

Patients are instructed to call their healthcare provider or go to the hospital if their temperature is 100.4 °F/38 °C or higher.

Cell Therapy 360 enrollment

Patients may enroll in support programs offered through Cell Therapy 360 after a certified CAR T treatment center determines that ABECMA is the right treatment for them.

Cell Therapy 360 Logo

Call us at 1-888-805-4555

Visit us at CellTherapy360.com

CAR=chimeric antigen receptor.

Learn more about ABECMA
efficacy

See more ABECMA safety
information